- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00315354
Popular Diets Study
22 de noviembre de 2016 actualizado por: David S. Ludwig, MD, PhD, Boston Children's Hospital
Popular Diets, Metabolism, and CVD Risk
The aim of this study is to evaluate the effects of three dominant dietary patterns - conventional low-fat, low-glycemic index (GI) and very-low-carbohydrate - on energy metabolism and heart disease risk factors following weight loss in obese young adults in a feeding study
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
For most of the last half century, reduction in fat intake has been the primary nutritional approach for the prevention and treatment of obesity and cardiovascular disease (CVD).
Over the last few years, very low carbohydrate (Atkins-type) diets have achieved great popularity, with publication of several studies suggesting greater weight loss and improvements in CVD risk factors over 3 to 6 months.
Recently, a third dietary approach focused on glycemic index (GI) has generated interest.
However, few studies have compared the effects of these diets on body weight regulation and risk for CVD.
The primary hypotheses of this study are that any diet that lowers the postprandial rise in blood glucose (very-low-carbohydrate or low-GI) will have beneficial effects on the physiological adaptations to weight loss and on some CVD risk factors.
However, other CVD risk factors will be adversely affected by a very-low-carbohydrate vs. a low-GI diet.
Preliminary data provide strong support for these hypotheses, by showing that resting energy expenditure declines less and CVD risk factors improve more with weight loss on a low-glycemic load diet compared to a conventional low-fat diet.
This application proposes a cross-over feeding design to study the effects of three diets following 12.5% weight loss in obese young adult subjects (n = 24, age 18 to 40 years).
The diets are: 1) conventional low-fat, with 60% carb, 20% fat, 20% protein; 2) low-GI with 40% carb, 40% fat, 20% protein; and 3) very-low-carbohydrate with 10% carb, 60% fat, 30% protein.
The primary outcome is resting energy expenditure (indirect calorimetry).
Secondary outcomes include total energy expenditure (doubly labeled water), thermic effect of food (indirect calorimetry), physical activity (accelerometry), insulin resistance and B-cell function (frequently-sampled OGTT), blood lipids, blood pressure and measures of systemic inflammation and coagulopathy.
This study should have major public health implications to the millions of Americans currently following diets to decrease body weight and risk for heart disease.
Tipo de estudio
Intervencionista
Inscripción (Actual)
24
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Children's Hospital Boston
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 40 años (Adulto)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- BMI ≥ 27 kg/m2
- Willing and able to come to the GCRC 5 days per week to consume a supervised meal and pick-up food for all other meals
- Available for scheduled hospital admissions
- Willing to abstain from alcohol consumption for the duration of the study
- If female, regular menstrual cycles (defined as 26 to 30 days between cycles; no more than one day variation in the duration of menstrual flow)
Exclusion Criteria:
- Weight > 350 lbs
- Change in body weight (± 10%) over preceding year
- Taking any medications or dietary supplements that might affect body weight, appetite, or energy expenditure
- Smoking (1 cigarette in the last week)
- High levels of physical activity
- Currently following a special diet
- Abnormal laboratory screening tests
- Type 2 diabetes mellitus
- Allergies or aversions to foods on the study menu
- Previous diagnosis of an eating disorder or any other mental health disorder
- If female, pregnant in the past 12 months or planning to become pregnant during the study period
- If female, lactating in the preceding 12 months
- If taking birth control medication, change in medication in previous 3 months or plans to change medication during the study period
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: 2
Dieta baja en grasas
|
Feeding protocol, all foods prepared in a metabolic kitchen
|
|
Experimental: 1
Low glycemic index diet
|
Feeding protocol, all foods prepared in a metabolic kitchen
|
|
Comparador activo: 3
Very low carbohydrate diet
|
Feeding protocol, all foods prepared in a metabolic kitchen
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
resting energy expenditure using indirect calorimetry in the fasting state
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
insulin resistance assessed by frequently-sampled oral glucose tolerance test
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
thyroid function tests
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
total energy expenditure using doubly labeled water methodology
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
thermic effect of food using indirect calorimetry
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
physical activity using accelerometry
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
serum lipids
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
plasminogen activator inhibitor-1
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
C-reactive protein
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
blood pressure
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
hunger/appetite
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
insulin 30 minutes after oral glucose (as an effect modifier)
Periodo de tiempo: baseline
|
baseline
|
|
|
Core temperature
Periodo de tiempo: End of each dietary period
|
End of each dietary period
|
|
|
secreted frizzle-related protein-4
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
heme-oxygenase
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
Irisin
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
fibroblast growth factor-21
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
chemerin
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
trimethylamine N-oxide
Periodo de tiempo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
alanine aminotransferase
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
Uric acid
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
insulin
Periodo de tiempo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
ghrelin
Periodo de tiempo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
gastric inhibitory peptide
Periodo de tiempo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
GLP1
Periodo de tiempo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
PYY
Periodo de tiempo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
Amylin
Periodo de tiempo: fasting and postprandial, end of each dietary period
|
fasting and postprandial, end of each dietary period
|
|
|
Leptin
Periodo de tiempo: end of each dietary period
|
end of each dietary period
|
|
|
Metabolomic analysis
Periodo de tiempo: end of each dietary period
|
Evaluate the effect of diet on metabolomic profile in plasma, with the aim of assessing dietary adherence and exploring diet-disease mechanisms
|
end of each dietary period
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Cara B Ebbeling, PhD, Boston Children's Hospital
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Walsh CO, Ebbeling CB, Swain JF, Markowitz RL, Feldman HA, Ludwig DS. Effects of diet composition on postprandial energy availability during weight loss maintenance. PLoS One. 2013;8(3):e58172. doi: 10.1371/journal.pone.0058172. Epub 2013 Mar 6.
- Ebbeling CB, Swain JF, Feldman HA, Wong WW, Hachey DL, Garcia-Lago E, Ludwig DS. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA. 2012 Jun 27;307(24):2627-34. doi: 10.1001/jama.2012.6607.
- Hron BM, Ebbeling CB, Feldman HA, Ludwig DS. Hepatic, adipocyte, enteric and pancreatic hormones: response to dietary macronutrient composition and relationship with metabolism. Nutr Metab (Lond). 2017 Jul 5;14:44. doi: 10.1186/s12986-017-0198-y. eCollection 2017.
- Esko T, Hirschhorn JN, Feldman HA, Hsu YH, Deik AA, Clish CB, Ebbeling CB, Ludwig DS. Metabolomic profiles as reliable biomarkers of dietary composition. Am J Clin Nutr. 2017 Mar;105(3):547-554. doi: 10.3945/ajcn.116.144428. Epub 2017 Jan 11. Erratum In: Am J Clin Nutr. 2022 Feb 9;115(2):601.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de abril de 2006
Finalización primaria (Actual)
1 de junio de 2010
Finalización del estudio (Actual)
1 de abril de 2013
Fechas de registro del estudio
Enviado por primera vez
14 de abril de 2006
Primero enviado que cumplió con los criterios de control de calidad
14 de abril de 2006
Publicado por primera vez (Estimar)
18 de abril de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
23 de noviembre de 2016
Última actualización enviada que cumplió con los criterios de control de calidad
22 de noviembre de 2016
Última verificación
1 de noviembre de 2016
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 1R01DK072428 (Subvención/contrato del NIH de EE. UU.)
- R01DK072428 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .